These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Inhibition of type A monoamine oxidase by 1-methyl-4-phenylpyridine.
    Author: Takamidoh H, Naoi M, Nagatsu T.
    Journal: Neurosci Lett; 1987 Jan 27; 73(3):293-7. PubMed ID: 3494215.
    Abstract:
    1-Methyl-4-phenylpyridine (MPP+) is now confirmed to be one of the oxidative products of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by type B monoamine oxidase (MAO-B) and is considered to cause a parkinsonism-like syndrome. We studied the effect of MPP+ on type A monoamine oxidase (MAO-A) activity in mitochondria prepared from various sources. By kinetic analysis, MPP+ was found to inhibit MAO-A in competition with the substrate, kynuramine. The Ki value of MAO-A with MPP+ in human brain synaptosomal mitochondria (1.3 microM) was much lower than the Ki values of MAO-A in other organs. Among the MAO-A samples, MAO-A in intrasynaptosomal mitochondria from human brain was the most sensitive to MPP+. The Ki value of MAO-A with MPP+ in striatum (1.6 microM and 2.0 microM for MAO-A prepared from putamen and from caudate) was similar to the Ki value of MAO-A in synaptosomes from cortex. The difference in the Ki values of MPP+ for MAO-A from various sources was considered to be due to the difference in lipid components of mitochondria. The possible significance of the inhibition of MAO-A was discussed in terms of the etiology of parkinsonism.
    [Abstract] [Full Text] [Related] [New Search]